Population-based incidence and mortality of community-acquired pneumonia in Germany.

Population-based incidence and mortality of community-acquired pneumonia in Germany.

<h4>Background</h4>Little information on the current burden of community-acquired pneumonia (CAP) in adults in Germany is available.<h4>Methods</h4>We conducted a retrospective cohort study using a representative healthcare claims database of approx. 4 million adults to estim...

Full description

Bibliographic Details
Main Authors:	Christian Theilacker, Ralf Sprenger, Friedhelm Leverkus, Jochen Walker, Dennis Häckl, Christof von Eiff, Julia Schiffner-Rohe
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2021-01-01
Series:	PLoS ONE
Online Access:	https://doi.org/10.1371/journal.pone.0253118

Similar Items

Pneumococcal vaccination rates in immunocompromised patients-A cohort study based on claims data from more than 200,000 patients in Germany.
by: Niklas Schmedt, et al.
Published: (2019-01-01)

Pneumococcal vaccination rates in immunocompromised patients in Germany: A retrospective cohort study to assess sequential vaccination rates and changes over time.
by: Ralf Sprenger, et al.
Published: (2022-01-01)

Pneumococcal vaccination rates in immunocompromised patients in Germany: A retrospective cohort study to assess sequential vaccination rates and changes over time
by: Ralf Sprenger, et al.
Published: (2022-01-01)

Efficacy of PPV23 in Preventing Pneumococcal Pneumonia in Adults at Increased Risk--A Systematic Review and Meta-Analysis.
by: Julia Schiffner-Rohe, et al.
Published: (2016-01-01)

Mathematical modeling of pneumococcal transmission dynamics in response to PCV13 infant vaccination in Germany predicts increasing IPD burden due to serotypes included in next-generation PCVs
by: Matthias Horn, et al.
Published: (2023-01-01)

Mathematical modeling of pneumococcal transmission dynamics in response to PCV13 infant vaccination in Germany predicts increasing IPD burden due to serotypes included in next-generation PCVs.
by: Matthias Horn, et al.
Published: (2023-01-01)

Streptococcus pneumoniae re-emerges as a cause of community-acquired pneumonia, including frequent co-infection with SARS-CoV-2, in Germany, 2021
by: Juliane Ankert, et al.
Published: (2023-05-01)

Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany
by: Felicitas Kühne, et al.
Published: (2023-12-01)

Epidemiology and Risk Factors of Clostridioides difficile Infections in Germany: A Health Claims Data Analysis
by: Thomas Weinke, et al.
Published: (2023-04-01)

Praktische Aspekte bei der Anwendung von Propensity Scores
by: Großhennig, Anika, et al.
Published: (2024-01-01)

Incidence of Antibiotic Treatment Failure in Patients with Nursing Home-Acquired Pneumonia and Community Acquired Pneumonia
by: Mariana Lopes, et al.
Published: (2021-01-01)

Mycoplasma pneumoniae and Chlamydia spp. Infection in Community-Acquired Pneumonia, Germany, 2011–2012
by: Roger Dumke, et al.
Published: (2015-03-01)

Antibody Profiling of COVID-19 Patients in an Urban Low-Incidence Region in Northern Germany
by: Werner Solbach, et al.
Published: (2020-09-01)

The incidence of acute renal failure and high mortality rate in elderly patients hospitalized with community acquired pneumonia
by: E. Lubart, et al.
Published: (2023-08-01)

Determinants of Mortality for Ventilated Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia
by: Hayley Motowski, MD, et al.
Published: (2023-03-01)

Community-acquired pneumonia by Chlamydophila pneumoniae: a clinical and incidence study in Brazil
by: Maria Bernadete Chedid, et al.

Bacterial etiology and mortality rate in community-acquired pneumonia, healthcare-associated pneumonia and hospital-acquired pneumonia in Thai university hospital
by: Jaturon Poovieng, et al.
Published: (2022-05-01)

Mortality, incidence, and microbiological documentation of ventilated acquired pneumonia (VAP) in critically ill patients with COVID-19 or influenza
by: Guillaume Laurichesse, et al.
Published: (2023-10-01)

Effect of corticosteroids on mortality in patients with community-acquired pneumonia
by: Shangzhong Chen, et al.
Published: (2023-09-01)

Risk factors for mortality in patients with acquired pneumonia in the community
by: Jorge Miranda Chaviano, et al.
Published: (2017-01-01)

Prognostic factors of mortality in elderly with community acquired pneumonia
by: Đordjević Ivanka, et al.
Published: (2010-01-01)

Predictive mathematical model of mortality for community acquired pneumonia
by: Pedro Julio García Álvarez, et al.
Published: (2018-03-01)

Surrogatvalidierung durch Korrelation und Surrogate Threshold Effect – Ergebnisse von Simulationsstudien
by: Gillhaus, Johanna, et al.
Published: (2017-01-01)

Comprehensive risk assessment for hospital-acquired pneumonia: sociodemographic, clinical, and hospital environmental factors associated with the incidence of hospital-acquired pneumonia
by: Bo-Guen Kim, et al.
Published: (2022-01-01)

Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study
by: Wolfgang Miesbach, et al.
Published: (2019-11-01)

RISK FACTORS FOR MORTALITY IN INTENSIVE CARE UNIT-ACQUIRED PNEUMONIA DUE TO KLEBSIELLA PNEUMONIAE
by: Sönmez Ufuk, et al.
Published: (2023-09-01)

Effect of vaccination on morbidity and mortality from community-acquired pneumonia
by: T. A. Bayanova, et al.
Published: (2024-03-01)

Factors associated with mortality in immunocompetent patients with hospital-acquired pneumonia
by: Pavaruch Sangmuang, et al.
Published: (2019-01-01)

PCV13 Vaccination of Adults against Pneumococcal Disease: What We Have Learned from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA)
by: Christian Theilacker, et al.
Published: (2022-01-01)

The impact of regional deprivation on stroke incidence, treatment, and mortality in Germany
by: Matthias Hans Belau, et al.
Published: (2023-02-01)

Is the long-term mortality similar in COVID-19 and community-acquired pneumonia?
by: Raúl Méndez, et al.
Published: (2023-10-01)

Predicting 1-year mortality after hospitalization for community-acquired pneumonia.
by: Ane Uranga, et al.
Published: (2018-01-01)

Biomarkers of cardiac dysfunction and mortality from community-acquired pneumonia in adults.
by: Catherina L Chang, et al.
Published: (2013-01-01)

No evidence of difference in mortality with amoxicillin versus co-amoxiclav for hospital treatment of community-acquired pneumonia
by: Wei, J, et al.
Published: (2024)

Safety analysis of new medications in clinical trials: a simulation study to assess the differences between cause-specific and subdistribution frameworks in the presence of competing events
by: Astrid Genet, et al.
Published: (2023-07-01)

Implementation of a ventilator care bundle to reduce the incidence of ventilator acquired pneumonia
by: Mandal AK, et al.
Published: (2011-06-01)

Risk Factors and Mortality of Elderly Patients with Hospital-Acquired Pneumonia of Carbapenem-Resistant Klebsiella pneumoniae Infection
by: Zhou C, et al.
Published: (2023-10-01)

Whole-Blood Gene Expression Profiles Associated with Mortality in Community-Acquired Pneumonia
by: Diego Viasus, et al.
Published: (2023-02-01)

Mortality predictors in patients with severe community-acquired pneumonia requiring ICU admission
by: Ali O. Abdel Aziz, et al.
Published: (2016-06-01)

CURB 65 score as a predictor of early mortality in hospital-acquired pneumonia
by: Nur R Oktariani, et al.
Published: (2019-01-01)